Gamida Cell $23 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the representative of the underwriters in connection with the $23 million SEC-registered follow-on offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq Global Select Market under the symbol “GMDA.”
Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge, an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an intrinsic NK cell therapy candidate being investigated for the treatment of hematologic malignancies.
The Davis Polk corporate team included partner Derek Dostal and associates Steven Glendon and Katherine Warshauer. Partner David R. Bauer and associates Alison T. Chin and Adrian Rabin provided intellectual property advice. The tax team included partner Michael Farber and associates Kelli A. Rivers and Ted Lee. Members of the Davis Polk team are based in the New York and London offices.